The India vaccine market was valued at INR 118.76 Billion in 2024, driven by the high burden of infectious diseases, rising strategic collaborations, and increased focus on local vaccine production capabilities in the country. The market is expected to grow at a CAGR of 8.80% during the forecast period of 2025-2034, with the values likely to reach INR 276.03 Billion by 2034.
Base Year
Historical Year
Forecast Year
In India, the rising burden of infectious diseases and the growing awareness about vaccination and its benefits are anticipated to drive market demand in the forecast period.
Increased government immunization programs and the rising strategic collaborations between the government and private sector are major trends propelling the market growth.
The market share is influenced by the advancements in vaccine technology, such as the introduction of mRNA vaccines and conjugate vaccines, and the rising focus on local vaccine production capabilities.
Value in INR Billion
2025-2034
India Vaccine Market Outlook
*this image is indicative*
A vaccine is a biological preparation designed to provide acquired immunity against a disease. A vaccine may include the strain, toxin, or one of the surface proteins of a dead or weakened microorganism that resembles the structure of a pathogen. Vaccines can be both therapeutic which offer immunity against a disease which has occurred or prophylactic which is administered to prevent an infection that may occur in the future.
The India vaccine market has seen a significant increase in demand for vaccines, especially after the sudden outbreak of COVID-19. With the government’s continuous efforts and awareness programs to promote the usage of vaccines, the masses have become more comfortable and familiar with vaccinations, which is expected to add to the market value in the coming years.
The rising number of private companies in India has also aided in the growth of the market share. Many pharmaceutical and biotechnology firms have made efforts to offer low-cost vaccine solutions and are gradually turning their attention to innovation to elevate their revenues. The government is also fostering market expansion by easing the rules and regulations and inviting foreign investments in order to accelerate the establishment of a better medical research infrastructure. Considering these factors, India is poised to emerge as a global manufacturing hub for vaccines in the forecast period.
Increased Focus on Domestic Production of Vaccines to Affect the Indian Market Landscape Significantly
Integrating the latest technologies into vaccine development, India has successfully developed four indigenous COVID-19 vaccines, namely, ZyCoV-D- the world’s first DNA Vaccine, India’s first protein subunit vaccine- CORBEVAXTM along with iNCOVACC, the first intranasal COVID-19 vaccine. In June 2023, GEMCOVAC™-19, the world’s first mRNA vaccine was revealed as a part of the Mission COVID Suraksha program. Such initiatives that focus on advancing local vaccine production capabilities indicate that the growth of the India vaccine market is certain in the upcoming years.
Shifting focus from COVID-19, the region is also making strides in other areas of development as well. Under the partnership of Serum Institute of India and Panacea Biotec, the country is headed to develop its first dengue vaccine. The two companies have applied for an Expression of Interest for collaborative Phase III clinical trials, moving closer to getting the vaccination ready to hit the markets.
Rising Government Immunization Programs is Fuelling India Vaccine Market Demand
The introduction of the Universal Immunization Program (UIP) aimed at raising immunization coverage against treatable diseases in the nation has substantially increased the market growth. Within the span of 5 years, the country has vaccinated approximately 348 million children under the measles-rubella vaccination campaign occurring nationwide. With such potential, the region is set to add to the global vaccine market share as well. Thus, the rising immunization programs by the government are expected to facilitate high vaccination coverage across the country, which will also support market expansion.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is witnessing several trends and developments to improve the current scenario in India. Some of the notable trends are as follows:
| Key Trends | Impact |
| Focus on Adult Vaccination | The growing emphasis on vaccinating adults and the elderly, instead of just focusing on children vaccination, is likely to shape the market dynamics. This trend is expected to address the need for vaccines against diseases like influenza, shingles, and pneumonia in older populations. |
| Rising Strategic Collaborations | One of the major market trends is the rising collaborations between the government and private sector, propelling large-scale vaccine production and distribution. Such strategic partnerships improve access and affordability of vaccines, thereby boosting the India vaccine market share. |
| Increasing Investment in Research and Development | In India, the market is influenced by the increasing investments in vaccine research and development by both government and private sectors. This is leading to the development of new and improved vaccines. |
| Development of Combination Vaccines | The rising development of combination vaccines is a significant market trend supported by the ability of these vaccines to protect against multiple diseases in a single shot. Such vaccines help improve immunization coverage and are set to aid market expansion. |
Market Breakup by Disease Type:
Market Breakup by Technology:
Market Breakup by Type:
Market Breakup by Patient Type:
Market Breakup by Route of Administration:
Market Breakup by End User:
Acellular or Subunit Vaccines to Dominate the Market Share Based on Technology
The market segmentation based on technology includes acellular or subunit vaccines, inactivated vaccines, live attenuated vaccines, and mRNA vaccines, among others. The acellular or subunit vaccines segment is expected to lead the market share and is likely to grow at a CAGR of 11.3% during the forecast period 2025-2034. Acellular or subunit vaccines experience a high market demand as they do not contain live pathogens and thus are considered comparatively safer than other vaccine alternatives. Additionally, these vaccines offer more stability in response to varying temperatures as well as are reported to exhibit targeted response.
Depending on factors such as healthcare infrastructure, population density, and economic development, different regions in India reveal varied market growth patterns. The Northern part, including regions like Delhi, Uttar Pradesh, and Punjab, represents a substantial market share driven by the high population density, increased focus on improving healthcare facilities, and rising immunization programs. The Southern states of India also hold a high market value which can be attributed to the better literacy rates and the rapid expansion of private hospitals and clinics, influencing the uptake of vaccines.
The key features of the market report comprise patent analysis, clinical trial analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
British multinational pharmaceutical and biotechnology company GlaxoSmithKline Plc has a prominent presence in the vaccine market in India. Besides its robust portfolio of vaccines, the global healthcare company is also actively engaged in spreading awareness about vaccination in the country.
Sanofi, a French multinational pharmaceutical and healthcare company, is one of the leading players in the market. It offers high-quality vaccines such as Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) and Shanchol™ Cholera Vaccine (Inactivated, Oral) I.P.
Pharmaceutical giant Pfizer, Inc. is known for its strong market reach and strategic partnerships for vaccine distribution. It is widely known for its Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) developed in partnership with BioNTech.
Merck & Co. Inc. specializes in the development of vaccines for both infectious diseases and chronic conditions. In June 2024, its Capvaxive vaccine was approved by the FDA to prevent the bacterial infections that cause pneumonia and meningitis in adults.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd, Panacea Biotec, Cadila Pharmaceuticals Ltd., Human Biological Institute, and Haffkine Bio-Pharmaceutical Corporation Ltd.
India Vaccine Market Regional Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Technology |
|
| Breakup by Type |
|
| Breakup by Patient Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share